Research and Markets (http://www.researchandmarkets.com/research/6bnh4h/hiv1_infection) has announced the addition of the "HIV-1 Infection - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for HIV-1 Infection.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Reasons to buy:

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for HIV-1 Infection
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding HIV-1 Infection pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned:

  • AltraVax Inc.
  • Aphios Corporation
  • Argos Therapeutics, Inc.
  • Arno Therapeutics, Inc.
  • Beth Israel Deaconess Medical Center, Inc.
  • Bionor Pharma ASA
  • Biosantech SA
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Chipscreen Biosciences Ltd
  • CompleGen, Inc.
  • Critical Outcome Technologies Inc.
  • Cytodyn Inc.
  • Dong-A ST Co., Ltd.
  • Enzo Biochem, Inc.
  • Evofem, Inc.
  • FIT Biotech Oy
  • Formune S.L.
  • Frontier Biotechnologies Co., Ltd
  • GeneCure LLC
  • Genetic Immunity, Inc
  • Gilead Sciences, Inc.
  • GlaxoSmithKline Plc
  • H-Phar S.A.
  • Heat Biologics, Inc.
  • (20+ Others)

For more information visit http://www.researchandmarkets.com/research/6bnh4h/hiv1_infection